Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME Study of 14C-JNJ-56136379 in Healthy Male Subjects
NCT03864601Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2019
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bersacapavir in Chronic Hepatitis B (CHB), sponsored by Janssen Pharmaceutical. Primary endpoints: Ratio of JNJ-56136379 Concentration and Total Radioactivity in Plasma, Ratio of JNJ-56136379 Concentration and Total Radioactivity in Plasma (AUC) and 2 more. Started Apr 2019; status: completed.
02
Drugs
bersacapavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03864601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03864601.